KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema. These candidates are designed to address unmet needs in rare disease and ophthalmology by improving patient convenience, reducing the burden of disease manifestations and potentially offering long‐lasting therapeutic benefit.
Founded in 2010 and headquartered in Cambridge, England, KalVista also maintains operations in Boston, Massachusetts. The company completed its initial public offering on the Nasdaq exchange in 2015 and has since advanced its pipeline through a combination of in‐house research, strategic collaborations and contract manufacturing partnerships. KalVista’s programs target patient populations in North America, Europe and other markets with significant unmet medical need.
KalVista is led by President and Chief Executive Officer Anna Berkenstock, PhD, who brings extensive experience in drug discovery, development and corporate strategy. The broader leadership team and board of directors draw on deep expertise in rare disease biology, protease chemistry and clinical development to guide the company’s strategic priorities and global growth.
AI Generated. May Contain Errors.
